Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493471 | 0.84 | LMNA (0.68) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493465 | 0.84 | ALDH1A1 (0.67) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493482 | 0.84 | USP2 (0.77) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493487 | 0.83 | ALDH1A1 (0.79) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493435 | 0.81 | ALDH1A1 (0.79) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493472 | 0.81 | POLB (0.68) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29958944 | 0.80 | KMT2A (0.83) | MAPK1KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL859415 | 0.79 | ALDH1A1 (0.74) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1493401 | 0.79 | ALDH1A1 (0.64) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1610031 | 0.78 | POLB (1.00) | MAPK1KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MAPK1 3086/4885KMT2A 1510/4885MEN1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.